Edition:
India

Horizon Pharma PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

24.47USD
10:48pm IST
Change (% chg)

$-0.45 (-1.81%)
Prev Close
$24.92
Open
$24.79
Day's High
$24.99
Day's Low
$24.22
Volume
209,173
Avg. Vol
585,478
52-wk High
$29.44
52-wk Low
$12.58

Latest Key Developments (Source: Significant Developments)

Horizon Pharma Sells Rights To Ravicti & Ammonaps Outside N.America and Japan
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA PLC - ON DEC 28 SOLD RIGHTS TO RAVICTI & AMMONAPS OUTSIDE OF N. AMERICA, JAPAN TO MEDICAL NEED EUROPE AB, FOR $35 MILLION.HORIZON PHARMA - TO RETAIN RIGHTS TO RAVICTI & AMMONAPS/BUPHENYL IN NORTH AMERICA & JAPAN.HORIZON PHARMA PLC - WILL RETAIN RIGHTS TO RAVICTI AND AMMONAPS/BUPHENYL IN NORTH AMERICA AND JAPAN.HORIZON PHARMA PLC - WILL NO LONGER RECOGNIZE REVENUE FROM RAVICTI AND AMMONAPS SALES OUTSIDE OF NORTH AMERICA AND JAPAN.  Full Article

Horizon Pharma PLC And Hemoshear Therapeutics Enter Into Exclusive Drug Discovery Collaboration
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA PLC AND HEMOSHEAR THERAPEUTICS ENTER INTO EXCLUSIVE DRUG DISCOVERY COLLABORATION IN GOUT.HORIZON PHARMA PLC - FURTHER FINANCIAL TERMS WERE NOT DISCLOSED..HORIZON PHARMA PLC - UNDER TERMS OF AGREEMENT, HEMOSHEAR WILL RECEIVE UPFRONT PAYMENTS AND RESEARCH AND DEVELOPMENT FUNDING.HORIZON PHARMA PLC - HORIZON WILL RECEIVE EXCLUSIVE ACCESS TO HEMOSHEAR'S PROPRIETARY DISEASE MODELING PLATFORM TO DISCOVER NEW THERAPEUTICS FOR GOUT.  Full Article

Horizon Pharma Announces FDA Approval To Expand Age Range For Ravicti
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA PLC ANNOUNCES FDA APPROVAL TO EXPAND THE AGE RANGE FOR RAVICTI® (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID TO INCLUDE NEWBORNS.  Full Article

Horizon Pharma - Entered Into Settlement Agreement With Par Pharmaceutical
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA - ON SEPTEMBER 17, CO'S UNIT ENTERED INTO A SETTLEMENT AGREEMENT WITH PAR PHARMACEUTICAL RELATING TO RAVICTI ORAL LIQUID, 1.1 GM/ML.HORIZON PHARMA PLC - SETTLEMENT AGREEMENT PERTAINS TO ON-GOING PATENT INFRINGEMENT LITIGATION AGAINST PAR IN DSITRICT COURT.HORIZON PHARMA - PARTIES HAVE AGREED TO FILE STIPULATIONS OF DISMISSAL WITH COURTS REGARDING LITIGATION AND JOINT REQUEST FOR TERMINATION IN THE IPRS.HORIZON PHARMA - UNIT GRANTED PAR NON-EXCLUSIVE, ROYALTY-FREE LICENSE TO MANUFACTURE, COMMERCIALIZE PAR'S GENERIC VERSION OF RAVICTI IN U.S..HORIZON - SETTLEMENT AGREEMENT PROVIDES FULL SETTLEMENT, RELEASE BY PARTIES OF CLAIMS THAT RELATE TO PAR’S GENERIC VERSION OF RAVICTI OR LITIGATION OR IPRS.HORIZON PHARMA - AGREEMENT ALSO PERTAINS TO PETITIONS FOR INTER PARTES REVIEW WITH PATENT TRIAL & APPEAL BOARD WITH CERTAIN U.S. PATENTS FOR RAVICTI.HORIZON - UNDER SETTLEMENT AGREEMENT WITH PAR, LICENSE EFFECTIVE DATE IS JULY 1, 2025 - SEC FILING.HORIZON PHARMA - LICENSE GRANTED TO PAR FOR MANUFACTURE OF ITS GENERIC VERSION OF RAVICTI EFFECTIVE AFTER LICENSE EFFECTIVE DATE OF JULY 1, 2025.HORIZON -UNIT AGREED NOT TO SUE,ASSERT CLAIM AGAINST PAR FOR INFRINGEMENT OF PATENT & PATENT APPLICATION OWNED OR CONTROLLED BY UNIT DURING AGREEMENT.HORIZON - PAR AGREED NOT TO CHALLENGE THE VALIDITY OR ENFORCEABILITY OF THE LICENSED PATENTS.  Full Article

Horizon Pharma PLC Announces Q4 Non-Gaap Earnings Per Share $0.29
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Horizon Pharma Plc ::ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.29.SEES FY 2018 SALES $1.15 BILLION TO $1.18 BILLION.Q4 SALES $274.2 MILLION.Q4 GAAP LOSS PER SHARE $0.28.‍FULL-YEAR 2018 ADJUSTED EBITDA GUIDANCE OF $370 MILLION TO $395 MILLION​.Q4 EARNINGS PER SHARE VIEW $0.22, REVENUE VIEW $264.5 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $1.14 BILLION -- THOMSON REUTERS I/B/E/S.HORIZON PHARMA SAYS Q4 NET SALES DRIVEN BY CONTINUED STRONG GROWTH FROM CO'S ORPHAN & RHEUMATOLOGY BUSINESS UNITS​.  Full Article

Horizon Pharma Sees Krystexxa FY 2018 Sales Up More Than 50 Percent
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA SEES KRYSTEXXA FY 2018 SALES UP MORE THAN 50 PERCENT.HORIZON PHARMA PLC - INCREASING ITS ESTIMATED PEAK ANNUAL NET SALES EXPECTATIONS FOR EACH MEDICINE TO MORE THAN $750 MILLION.HORIZON PHARMA PLC INCREASES PEAK NET SALES GUIDANCE FOR KEY GROWTH DRIVERS AND ANNOUNCES RHEUMATOLOGY AND ORPHAN PIPELINE DEVELOPMENTS.  Full Article

Horizon Pharma Plc Announces Agreement To License Pre-Clinical Uricase Derivative From Medimmune
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA PLC ANNOUNCES AGREEMENT TO LICENSE PRE-CLINICAL URICASE DERIVATIVE (MEDI4945) FROM MEDIMMUNE.HORIZON PHARMA PLC - WILL PROVIDE MEDIMMUNE AN UPFRONT CASH PAYMENT AND FUTURE PAYMENTS CONTINGENT ON MEDI4945 DEVELOPMENT AND SALES MILESTONES.  Full Article

Horizon pharma plc announces Q3 non-gaap earnings per share $0.26
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Horizon Pharma PLC :Horizon Pharma PLC announces third-quarter and year-to-date 2017 results.Q3 Non-GAAP earnings per share $0.26.Q3 sales $271.6 million versus I/B/E/S view $259.7 million.Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S.Sees FY 2018 sales up more than 50 percent.Sees FY 2017 sales $1.03 billion to $1.05 billion.Q3 gaap loss per share $0.39.Horizon Pharma PLC - sees FY 2017 ‍adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million​.  Full Article

Horizon Pharma reports Q3 Non-GAAP earnings per share $0.26
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Horizon Pharma Plc : :Horizon Pharma plc announces third-quarter and year-to-date 2017 results.Q3 sales $271.6 million versus I/B/E/S view $259.7 million.Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $1.03 billion to $1.05 billion.Q3 GAAP loss per share $0.39.Q3 Non-GAAP earnings per share $0.26.Horizon Pharma plc says sees FY 2017 ‍adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million.Horizon Pharma says sees Krystexxa 2018 net sales up more than 50 percent​.  Full Article

Horizon Pharma says first patient enrolled in confirmatory Phase 3 clinical trial evaluating Teprotumumab
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Horizon Pharma Plc :Horizon Pharma Plc announces first patient enrolled in confirmatory Phase 3 clinical trial evaluating Teprotumumab for the treatment of moderate-to-severe active thyroid eye disease.  Full Article

Recordati to seek Canadian approval for kidney disease drug

TORONTO Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.